J-TEC, as subsidiary of Fujifilm, has submitted a clinical trial plan for the treatment of osteoarthrosis by its autologous chondrocyte tissue product “Jack”. Jack acquired manufacturing and marketing authorization in 2012 for traumatic cartilage defect in knee joint or transdermal osteochondritis. It was Japan’s first regenerative medicine product in the orthopedics field, covered by insurance since 2013. The company plans clinical trials at 10 institutes including Hiroshima and Shimane University.
J-TEC news release, July 20, 2018
J-TEC applies for osteoarthritis treatment using autologous chondrocyte tissue